Kuzmanović Elabjer Biljana, Marković Leon, Bjeloš Mirjana, Bušić Mladen, Miletić Daliborka, Kos Eva
University Eye Clinic, Faculty of Dental Medicine and Health Care Osijek, Faculty of Medicine Osijek, University Josip Juraj Strossmayer in Osijek, University Hospital "Sveti Duh", Zagreb, Croatia.
Clin Ophthalmol. 2020 Oct 30;14:3691-3697. doi: 10.2147/OPTH.S283655. eCollection 2020.
Inflammation is among the most important mechanisms in the pathogenesis of dry eye disease (DED), triggering the vicious circle of the disease. Reducing inflammation is an important target in dry eye disease treatment. Hydrocortisone is a low-potency corticosteroid with a low ocular penetration potential.
To document the effect of topical preservative-free hydrocortisone 0.335% (PFH, Softacort, Laboratoires Théa, France) on DED.
Retrospective data review of patients with mild to moderate DED, treated with PFH for 15 days. Clinical evaluations at Days 0 and 15 included the assessment of the central precorneal tear film thickness (CPTFT), fluorescein tear breakup time, Schirmer test, corneal grading staining (Oxford schema), ocular surface disease index (OSDI) spatial distribution of the precorneal tear film thickness, intraocular pressure (IOP) and local tolerance.
Data from 13 women and 2 men were collected. Mean age±SD was 51±5 years for women and 53±4 years for men. Clinical signs and symptoms significantly (all p<0.05) improved after 15 days of treatment. A significant positive correlation between the percentage of change in left eye CPTFT and that in the contralateral eye CPTFT was observed (p=0.003) as well as for both eyes and the left eye FTBUT (p=0.03). For the percentage of change in OSDI, the only significant correlation was with the percentage of change in right eye and FTBUT (p=0.03). IOP remained unchanged. No adverse events were recorded.
This retrospective data review confirms that topical PFH twice daily for 2 weeks significantly improves clinical signs and symptoms in patients with mild to moderate DED with no safety issues.
炎症是干眼疾病（DED）发病机制中最重要的机制之一，引发疾病的恶性循环。减轻炎症是干眼疾病治疗的一个重要目标。氢化可的松是一种低效皮质类固醇，眼部渗透潜力较低。
记录局部应用0.335%无防腐剂氢化可的松（PFH，Softacort，法国Thea实验室）治疗DED的效果。
对轻度至中度DED患者进行回顾性数据审查，这些患者接受PFH治疗15天。第0天和第15天的临床评估包括中央角膜前泪膜厚度（CPTFT）、荧光素泪膜破裂时间、泪液分泌试验、角膜分级染色（牛津模式）、眼表疾病指数（OSDI）、角膜前泪膜厚度的空间分布、眼压（IOP）和局部耐受性评估。
收集了13名女性和2名男性的数据。女性的平均年龄±标准差为51±5岁，男性为53±4岁。治疗15天后，临床体征和症状显著改善（所有p<0.05）。观察到左眼CPTFT变化百分比与对侧眼CPTFT变化百分比之间存在显著正相关（p=0.003），双眼和左眼的FTBUT也存在显著正相关（p=0.03）。对于OSDI变化百分比，唯一显著的相关性是与右眼变化百分比和FTBUT（p=0.03）。眼压保持不变。未记录到不良事件。
这项回顾性数据审查证实，每天两次局部应用PFH，持续2周，可显著改善轻度至中度DED患者的临床体征和症状，且无安全问题。
